Influence of Glucose on Metabolism and Clinical Symptoms of Patients With Parkinson's Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50-80
SponsorUniversity Hospital Schleswig-Holstein

About this trial

Many patients with Parkinson's Disease (PD) report an increased consumption of fast-acting sugars. This tendency to consume sweet, high-sugar foods occurs in some patients even before the onset of cardinal motor symptoms. Some recent studies have demonstrated that PD patients have an increased consumption of fast-acting carbohydrates compared to healthy controls. However, the reason for this change in eating behavior has not yet been adequately explained. It is discussed that the increased sugar intake leads to an increased dopamine release in the brain via an increase in insulin and thus to an improvement in clinical symptoms. This study investigates the influence of fast-acting carbohydrates on insulin and glucose blood levels as well as motor and non-motor symptoms in patients with PD using an oral glucose tolerance test and a placebo oral glucose tolerance test in a crossover design.

Eligibility criteria

Qualifiers

Diagnosis of Parkinson's Disease, stage Hoehn & Yahr 1.5-3

Ability to pause antiparkinsonian medication in the morning without relevant impairment

Capacity to give consent (determined in doubt by two independent neurologists, MOCA ≥18) and written informed consent.

Patients are between 50 and 80 years of age, with exceptions for a maximum of 5 additional patients enrolled per group

Disqualifiers

Other significant neurological diseases primarily affecting the central nervous system (e.g., multiple sclerosis)

Diagnosis of diabetes mellitus or prediabetes

Use of medications that affect glucose metabolism, such as antidiabetics, glucocorticoids, ciclosporin, tacrolimus, sirolimus, beta-blockers, thiazide diuretics, beta-2 adrenoreceptor agonists, theophylline, Clozapine, olanzapine, paliperidone, quetiapine, risperidone, tricyclic antidepressants, mirtazapine, mianserin, carbamazepine, gabapentin, pregabalin, valproic acid, lithium, antiretroviral drugs, statins

cardiac or brain pacemakers

Trial design

Treatments tested in this trial

  • Oral Glucose Tolerance Test
  • Placebo Oral Glucose Tolerance Test

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators